Genomic medicine and targeted therapy for solid tumors

Journal of Surgical Oncology

Volumn 111, Issue 1, 2015, Pages 38-42

  Stevens, Emily A ^a,b   Rodriguez, Cristina P ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

Human genetics; Individualized medicine; Molecular targeted therapy; Mutation; Neoplasm

Indexed keywords

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; COLORECTAL CANCER; GENOMICS; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; SOLID TUMOR; SYSTEMIC THERAPY; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS; PROGNOSIS;

TUMOR MARKER;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84920749964     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23699     Document Type: Article

References (53)

1. Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042. DOI: 10.1056/NEJM200104053441402
2. Fong PC, Boss DS, Yap TA, et al.: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-134.DOI: 10.1056/NEJMoa0900212
3. Scholl C, Frohling S, Dunn IF, et al.: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009;137:821-834.DOI: 10.1016/j. cell.2009.03.017
4. Hurvitz SA, Pietras RJ: Rational management of endocrine resistance in breast cancer: A comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 2008;113:2385-2397.DOI: 10.1002/cncr.23875
5. Harris L, Fritsche H, Mennel R, et al.: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312.DOI: 10.1200/JCO.2007.14.2364
6. Dowsett M, Cuzick J, Wale C, et al.: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 2010;28:1829-1834.DOI: 10.1200/JCO.2009.24.4798
7. Miller TW, Hennessy BT, Gonzalez-Angulo AM, et al.: Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-2413.DOI: 10.1172/JCI41680
8. Bachelot T, Bourgier C, Cropet C, et al.: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 2012;30:2718-2724. DOI: 10.1200/JCO.2011.39.0708
9. Baselga J, Campone M, Piccart M, et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-529.DOI: 10.1056/NEJMoa1109653
10. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.DOI: 10.1056/NEJMoa052122
11. Moja L, Tagliabue L, Balduzzi S, et al.: Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012;4:CD006243.
12. Geyer CE1, Forster J, Lindquist D, et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
13. Baselga J1, Cortés J, Kim SB, et al.: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-119.DOI: 10.1056/NEJMoa1113216
14. Walther A, Johnstone E, Swanton C, et al.: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9: 489-499. DOI: 10.1038/nrc2645
15. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al.: Biomarkers predicting clinical outcome of epidermal growth factor receptortargeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009;101:1308-1324.DOI: 10.1093/jnci/djp280
16. De Roock W, Claes B, Bernasconi D, et al.: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11:753-762.DOI: 10.1016/S1470-2045(10)70130-3
17. Karapetis CS, Khambata-Ford S, Jonker DJ, et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765.DOI: 10.1056/NEJMoa0804385
18. Amado RG, Wolf M, Peeters M, et al.: Wild-type KRAS is required for panitumumab efficacy in patients withmetastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.DOI: 10.1200/JCO.2007.14.7116
19. Bokemeyer C, Bondarenko I, Makhson A, et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.DOI: 10.1200/JCO.2008.20.8397
20. Van Cutsem E, Peeters M, Siena S, et al.: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664. DOI: 10.1200/JCO.2006.08.1620
21. Liao X, Lochhead P, Nishihara R, et al.: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-1606.DOI: 10.1056/NEJMoa1207756
22. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al.: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807.DOI: 10.1200/JCO.2003.11.069
23. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.DOI: 10.1056/NEJMoa040938
24. Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.DOI: 10.1056/NEJMoa0810699
25. Rosell R, Carcereny E, Gervais R, et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.DOI: 10.1016/S1470-2045(11)70393-X
26. Sequist LV, Yang JC, Yamamoto N, et al.: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-3334.DOI: 10.1200/JCO.2012.44.2806
27. Godin-Heymann N, Ulkus L, Brannigan BW, et al.: The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 2008;7:874-879.DOI: 10.1158/1535-7163.MCT-07-2387
28. Yip PY, Yu B, CooperWA, et al.: Patterns ofDNAmutations andALK rearrangement in resected node negative lung adenocarcinoma. J Thorac Oncol 2013;8:408-414.DOI: 10.1097/JTO.0b013e318283558e
29. Park HS, Lee JK, Kim DW, et al.: Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 2012;77:288-292. DOI: 10.1016/j.lungcan.2012.03.004
30. Kwak EL, Bang YJ, Camidge DR, et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.DOI: 10.1056/NEJMoa1006448
31. Camidge DR, Bang YJ, Kwak EL, et al.: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 2012;13:1011-1019.DOI: 10.1016/S1470-2045(12)70344-3
32. Shaw AT, Kim DW, Nakagawa K, et al.: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.DOI: 10.1056/NEJMoa1214886
33. Marchetti A, Felicioni L, Malatesta S, et al.: Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29:3574-3579.DOI: 10.1200/JCO.2011.35.9638
34. Planchard D, Mazieres J, Riely G, et al.: Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation- positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2013;pp. abstract 8009.
35. Nikiforov YE: Thyroid carcinoma: Molecular pathways and therapeutic targets. Mod Pathol 2008;21:S37-S43.DOI: 10.1038/modpathol.2008.10
36. Kloos RT, Ringel MD, Knopp MV, et al.: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-1684.DOI: 10.1200/JCO.2008.18.2717
37. Gupta-Abramson V1, Troxel AB, Nellore A, et al.: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-4719.
38. Brose. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol 2013;pp. abstract 4.
39. Wells SA, Jr., Santoro M: Targeting the RET pathway in thyroid cancer. Clin Cancer Res 2009;15:7119-7123.
40. Wells SA, Jr., Robinson BG, Gagel RF, et al.: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-141.DOI: 10.1200/JCO.2011.35.5040
41. Shoffski. An international, double-blind, randomized, placebocontrolled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma patients with documented RECIST progression at baseline. J Clin Oncol 2012;pp. abstract 5508.
42. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.DOI: 10.1056/NEJMoa053422
43. Vermorken JB, Mesia R, Rivera F, et al.: Platinumbased chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.DOI: 10.1056/NEJMoa08 02656
44. Curtin JA, Fridlyand J, Kageshita T, et al.: Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-2147.DOI: 10.1056/NEJMoa050092
45. Lovly CM, Dahlman KB, Fohn LE, et al.: Routine multiplex mutational profiling of melanomas enables enrollment in genotypedriven therapeutic trials. PLoS ONE 2012;7:e35309.DOI: 10.1371/journal.pone.0035309
46. Hauschild A, Grob JJ, Demidov LV, et al.: Dabrafenib in BRAFmutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-365.DOI: 10.1016/S0140-6736(12)60868-X
47. Sosman JA, Kim KB, Schuchter L, et al.: Survival in BRAF V600- mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-714.DOI: 10.1056/NEJMoa1112302
48. Hauschild A, Grob JJ, Demidov LV: An update on BREAK-3a phase III, randomized trial: Dabrafenib versus dacarbazine in patients with BRAF V600E-positive mutation metastatic melanoma. J Clin Oncol 2013;31:(supplement): abstract 9013.
49. Kim KB, Kefford R, Pavlick AC, et al.: Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAFmutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-489.DOI: 10.1200/JCO.2012.43.5966
50. Flaherty KT, Infante JR, Daud A, et al.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-1703.DOI: 10.1056/NEJMoa1210093
51. Experts in Chronic Myeloid L. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 2013;121:4439-4442.DOI: 10.1182/blood-2013-03- 490003
52. Djalalov S, Beca J, Hoch JS, et al.: Cost effectiveness of EML4- ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol 2014;32:1012-1019.DOI: 10.1200/JCO.2013.53.1186
53. Pritchard CC, Salipante SJ, Koehler K, et al.: Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn 2014;16:56-67.DOI: 10.1016/j.jmoldx.2013.08.004